ABEONA THERAPEUTICS INC. Net Income (Loss) Available to Common Stockholders, Diluted
ABEONA THERAPEUTICS INC. (ABEO) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$20.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$20.19M, a 117.76% decline year-over-year.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$21.49M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$5.16M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $113.67M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was $67.08M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$63.73M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$21.87M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$14.53M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$20.19M 10-Q · filed 2026-08-13 | -$37.27M 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | -$21.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$26.65M derived: sum of 2 quarters · filed 2026-03-17 | $87.02M derived: sum of 3 quarters · filed 2026-08-13 | $67.08M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | -$5.16M 10-Q · filed 2025-11-12 | $108.51M derived: sum of 2 quarters · filed 2026-08-13 | $88.57M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $113.67M 10-Q · filed 2026-08-13 | $95.62M 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | -$9.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$39.56M derived: sum of 2 quarters · filed 2026-03-17 | -$53.01M derived: sum of 3 quarters · filed 2026-03-17 | -$63.73M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | -$30.27M 10-Q · filed 2025-11-12 | -$43.72M derived: sum of 2 quarters · filed 2025-11-12 | -$54.44M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$13.45M 10-Q · filed 2025-08-14 | -$24.17M 10-Q · filed 2025-08-14 | ||||
| 2023-06-30 | -$16.65M 10-Q · filed 2024-08-12 | -$25.76M 10-Q · filed 2024-08-12 | ||||
| 2016-12-31 | -$21.87M 10-K · filed 2017-03-30 | |||||
| 2015-12-31 | -$14.53M 10-K · filed 2017-03-30 | |||||
| 2014-12-31 | -$12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$14.84M derived: sum of 2 quarters · filed 2016-03-30 | -$28.07M derived: sum of 3 quarters · filed 2016-03-30 | -$29.65M 10-K · filed 2016-03-30 | ||
| 2014-09-30 | -$2.21M 10-Q · filed 2014-11-14 | -$15.44M derived: sum of 2 quarters · filed 2014-11-14 | -$17.03M 10-Q · filed 2014-11-14 | -$18.07M derived: sum of 4 quarters · filed 2015-03-31 | ||
| 2014-06-30 | -$13.23M 10-Q · filed 2014-08-14 | -$14.82M 10-Q · filed 2014-08-14 | -$15.86M derived: sum of 3 quarters · filed 2015-03-31 | -$16.76M derived: sum of 4 quarters · filed 2015-03-31 | ||
| 2014-03-31 | -$853.00K 10-Q · filed 2014-05-12 | -$2.62M derived: sum of 2 quarters · filed 2015-03-31 | -$3.52M derived: sum of 3 quarters · filed 2015-03-31 | -$2.66M derived: sum of 4 quarters · filed 2015-03-31 | ||
| 2013-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | -$2.67M derived: sum of 2 quarters · filed 2015-03-31 | -$1.80M derived: sum of 3 quarters · filed 2015-03-31 | $1.55M 10-K · filed 2015-03-31 | ||
| 2013-09-30 | -$899.00K 10-Q · filed 2014-11-14 | -$32.00K derived: sum of 2 quarters · filed 2014-11-14 | $3.32M 10-Q · filed 2014-11-14 | $22.47M derived: sum of 4 quarters · filed 2014-11-14 | ||
| 2013-06-30 | $867.00K 10-Q · filed 2014-08-14 | $1.16M 10-Q · filed 2013-08-14 | $4.22M 10-Q · filed 2014-08-14 | $4.51M 10-Q · filed 2013-08-14 | $23.37M derived: sum of 3 quarters · filed 2014-08-14 | $8.06M derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $3.35M 10-Q · filed 2014-05-12 | $22.50M derived: sum of 2 quarters · filed 2014-05-12 | $7.19M derived: sum of 3 quarters · filed 2014-05-12 | -$3.85M derived: sum of 4 quarters · filed 2014-05-12 | ||
| 2012-12-31 | $19.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $3.84M derived: sum of 2 quarters · filed 2014-03-26 | -$7.20M derived: sum of 3 quarters · filed 2014-03-26 | -$12.53M 10-K · filed 2014-03-26 | ||
| 2012-09-30 | -$15.31M 10-Q · filed 2013-11-14 | -$26.35M derived: sum of 2 quarters · filed 2013-11-14 | -$31.68M 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | -$11.04M 10-Q · filed 2013-08-14 | -$16.37M 10-Q · filed 2013-08-14 | ||||
| 2012-03-31 | -$5.33M 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |